bms204352 has been researched along with ethacrynic acid in 2 studies
| Studies (bms204352) | Trials (bms204352) | Recent Studies (post-2010) (bms204352) | Studies (ethacrynic acid) | Trials (ethacrynic acid) | Recent Studies (post-2010) (ethacrynic acid) |
|---|---|---|---|---|---|
| 49 | 1 | 12 | 2,291 | 64 | 126 |
| Protein | Taxonomy | bms204352 (IC50) | ethacrynic acid (IC50) |
|---|---|---|---|
| Chain A, GLUTATHIONE TRANSFERASE A1-1 | Homo sapiens (human) | 10 | |
| perilipin-5 | Homo sapiens (human) | 4.832 | |
| perilipin-1 | Homo sapiens (human) | 4.19 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 4.511 | |
| Glutathione S-transferase A1 | Homo sapiens (human) | 5 | |
| Glutathione S-transferase P | Homo sapiens (human) | 3.7 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 8.5 | |
| Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | 4.5 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 8.5 | |
| 60 kDa chaperonin | Escherichia coli | 4.95 | |
| 10 kDa chaperonin | Escherichia coli | 4.95 | |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | 3.85 | |
| large T antigen | Betapolyomavirus macacae | 100 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for bms204352 and ethacrynic acid
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |